nautika1: safety and tolerability of neoadjuvant alectinib in alk-positive nsclc
Published 2 years ago • 470 plays • Length 0:56Download video MP4
Download video MP3
Similar videos
-
3:04
management of frontline alk nsclc: brigatinib vs. alectinib
-
1:56
alex: alectinib is the best first-line therapy available for alk-positive nsclc
-
3:34
alk-positive nsclc: the role of treatment selection and sequencing
-
2:37
crown: lorlatinib in treatment-naïve patients with alk-positive advanced nsclc
-
1:42
next-generation alk inhibitors: treatment sequencing and resistance
-
5:44
updates in alk lung cancer: glass, alex, alta-1l and crown
-
1:18
real-world treatment patterns of alectinib in unselected spanish alk nsclc patients | oncotarget
-
2:05
alta-1l: brigatinib vs crizotinib in nsclc
-
3:44
alk inhibitors for acquired resistance: zykadia and alectinib
-
1:35
dr. brufsky on cdk 4/6 inihibitors in neoadjuvant breast cancer treatment
-
2:09
alta-1l: brigatinib vs crizotinib in alk ansclc
-
1:33
neoadjuvant egfr tki trials in nsclc
-
8:04
treating with alk inhibitors in nsclc
-
4:38
patterns of progression on crizotinib for alk nsclc
-
1:22
dr. crinò on crizotinib in alk nsclc
-
6:04
case study: progression on alk inhibitors in nsclc
-
3:47
pembrolizumab as treatment for oligometastatic nsclc
-
1:07
dr. massarelli on first-line alk nsclc treatment